U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
Wednesday, analysts at JMP Securities maintained a Market Outperform rating on Pharvaris B.V. (NASDAQ:PHVS) shares, with a steady price target of $55.00. The stock, currently trading at $15.09, has shown strong momentum with a nearly 10% gain over the past week, according to InvestingPro data. The company maintains a healthy financial position with more cash than debt on its balance sheet. The firm’s analyst, Jonathan Wolleben, highlighted the company’s upcoming milestones, particularly the anticipated Phase 3 data for its drug candidate deucrictibant, which is being developed for the treatment and prevention of Hereditary Angioedema (HAE) attacks.
Wolleben noted that while 2025 is a pivotal year for Pharvaris in terms of execution, the critical Phase 3 results for deucrictibant are expected in the first quarter of 2026 for on-demand treatment of HAE attacks, and in the second half of 2026 for prevention. The importance of these milestones is underscored by the potential for three approvals in the HAE landscape within this year, which could significantly boost the visibility of Pharvaris as the sole provider of an oral option for both the prevention and treatment of HAE attacks.
The analyst anticipates that the U.S. launches of deucrictibant could occur in 2027 for acute settings and in 2028 for prophylactic use. JMP Securities has projected peak sales estimates for deucrictibant to reach approximately $600 million for acute treatment and around $1.6 billion for prophylactic use. With a current market capitalization of $822 million and a strong liquidity position reflected in its current ratio of 12.6, Pharvaris appears well-positioned to fund its development programs.
The optimism surrounding Pharvaris is rooted in the company’s strategic positioning within the HAE market. With the potential for significant developments in the near term, Pharvaris is poised to capitalize on its unique offering in the HAE therapeutic space.
The company’s stock rating and price target have been reinforced by JMP Securities, reflecting confidence in Pharvaris’s trajectory and its ability to meet key clinical and regulatory milestones in the coming years. The analyst’s comments underscore the critical nature of the upcoming data and the potential market impact of the company’s product candidate. Based on InvestingPro’s Fair Value analysis, the stock appears fairly valued at current levels. Investors can access 8 additional ProTips and comprehensive financial metrics through an InvestingPro subscription to make more informed investment decisions.
In other recent news, Pharvaris has received orphan designation from the European Commission for its drug candidate deucrictibant, aimed at treating bradykinin-mediated angioedema. This designation complements a similar acknowledgment by the U.S. Food and Drug Administration, highlighting the drug’s potential benefits. The company is actively progressing with Phase 3 clinical trials to assess deucrictibant’s efficacy and safety in preventing hereditary angioedema (HAE) attacks. Recent data presented at the AAAAI/WAO Joint Congress demonstrated the drug’s sustained effectiveness in reducing HAE attacks and improving patients’ quality of life. Analysts from Citizens JMP and JMP Securities have maintained their positive outlook on Pharvaris, with both firms setting a price target of $55 for the company’s stock. These analysts have expressed confidence in the drug’s promising profile, noting its potential to offer a significant improvement over current treatment options. Pharvaris’s ongoing trials, including the RAPIDe-3 trial, are expected to yield results in the coming years, with top-line data anticipated by 2026. The company’s commitment to advancing deucrictibant as an oral treatment option for HAE aligns with its strategy to address unmet needs in the angioedema community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.